Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Hypertension 2Diabetes Mellitus, Type 2 2Cushing Syndrome 2ACTH Syndrome, Ectopic 2Pituitary ACTH Hypersecretion 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 45Carboplatin 33Bevacizumab 17liposomal doxorubicin 15Topotecan 12Taxes 10Gemcitabine 10Drug Therapy 6Cisplatin 6rucaparib 5mirvetuximab soravtansine 5Docetaxel 5Immunoglobulin G 4Doxorubicin 4Disulfides 4trebananib 3pembrolizumab 3olaparib 3Saline Solution 3Neoadjuvant Therapy 3Hyperthermic Intraperitoneal Chemotherapy 3Dexamethasone 3CP protocol 3niraparib 2cediranib 2Tamoxifen 2Specimen Handling 2Letrozole 2Glucose 2Cytoreduction Surgical Procedures 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Fallopian Tube Neoplasms × relacorilant × Clear all
NCT05257408 2025-04-16

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Corcept Therapeutics

Phase 3 Active not recruiting
381 enrolled 1 FDA
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡